Crohn’s Disease – China Drug Forecast and Market Analysis to 2022

  • Pages: 125
  • Published: January 2014
  • Format:
  • Report Code: GDHC212CFR
  • Add to Saved List

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Based on GlobalData’s primary research, the majority of Chinese gastroenterologists followthe ACG and/or the World Gastroenterology Organization (WGO) guidelines for the management of their CD patients. In a few cases, they also refer to the local treatment guidelines. Approximately 40% of the referrals for CD patients come from PCPs, while the rest arise from their colleagues or colorectal surgeons.


Overview of Crohn’s disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in China from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting the China Crohn’s disease market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.

Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease..

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

Make more informed business decisions from insightful and in-depth analysis of drug performance.

Obtain sales forecast for drugs from 2012-2022 in China.

Table of Contents

1Table of Contents1

1.1List of Tables4

1.2List of Figures6

2Executive Summary7

2.1Sales for CD in Canada in 2012–2022:8

2.2What ...

1Table of Contents1

1.1List of Tables4

1.2List of Figures6

2Executive Summary7

2.1Sales for CD in Canada in 2012–2022:8

2.2What Do Physicians Think?10



3.2Related Reports12

3.3Upcoming Related Reports13

4Disease Overview14

4.1Etiology and Pathophysiology14





4.4Quality of Life19

5Disease Management19

5.1Treatment Overview20



5.2.2Clinical Practice26

6Competitive Assessment27


6.2Strategic Competitor Assessment28

6.3Product Profiles – Major Brands29

6.3.1Remicade (infliximab)29

6.3.2Humira (adalimumab)34

6.3.3Cimzia (certolizumab pegol)39

6.3.4Other Marketed Products43



6.4.2Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases45

6.4.3Biosimilars in the Immunology Community45

6.4.4By the Numbers: Biosimilars in Development46

6.4.5The Impact of Biosimilars Will be Felt Through out the Pharmaceutical Industry48

7Opportunity and Unmet Need49


7.2Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach51

7.3More Therapies for Anti-TNF-Refractory Patients52

7.4Unmet Needs Gap Analysis52

7.5Targeted Therapies54

7.6Predictive Tools for Early Diagnosis and Treatment55

8Pipeline Assessment55


8.2Promising Drugs in Clinical Development56

8.2.1Entyvio (vedolizumab)58

8.2.2Stelara (ustekinumab)70

8.2.3Vercirnon (formerly GSK1605786)76

8.2.4Prochymal (Remestemcel-L)82

8.3Other Late-Stage Pipeline Products87


8.3.2RHB-104 (clarithromycin + clofazimine + rifabutin)90

9Market Outlook94

9.1Global Markets94

9.1.1Drivers and Barriers – Global Issues94



10.2Key Events104

10.3Drivers and Barriers104

10.3.1Driver: New product launches in 2015 of non-anti-TNF biologics will challenge the current anti-TNF market leaders104

10.3.2Driver: The pathway for biosimilar approval is already in place105

10.3.3Driver: Continued uptake of TNF inhibitors, particularly Remicade105

10.3.4Driver: Health Canada’s complete coverage of all drugs administered in the hospital improves patient access to IV drugs such as Remicade105

10.3.5Barrier: Government initiatives to the cut prices of generics will increase the rate of genericization106





11.4Forecasting Methodology114

11.4.1Diagnosed CD Patients115

11.4.2Percent Drug-Treated Patients115

11.4.3Drugs Included in Each Therapeutic Class115

11.4.4Launch and Patent Expiry Dates116

11.4.5General Pricing Assumptions116

11.4.6Individual Drug Assumptions118

11.4.7Generic Erosion119

11.4.8Pricing of Pipeline agents120

11.5Physicians and Specialists Included in This Study121

11.6Primary Research – Prescriber Survey122

11.7About the Authors123


11.7.2Global Head of Healthcare123

11.8About GlobalData124

11.9Contact Us124


List of tables

Table 1: CD: Key Metrics in the Canada7

Table 2: Symptoms of CD18

Table 3: Treatment Guidelines for CD22

Table 4: Most Commonly Prescribed Drugs ...

Table 1: CD: Key Metrics in the Canada7

Table 2: Symptoms of CD18

Table 3: Treatment Guidelines for CD22

Table 4: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 201324

Table 5: Leading Branded Drugs Used to Treat CD29

Table 6: Product Profile – Remicade31

Table 7: Remicade SWOT Analysis, 201333

Table 8: Product Profile – Humira36

Table 9: Humira SWOT Analysis, 201339

Table 10: Product Profile – Cimzia41

Table 11: Cimzia SWOT Analysis, 201343

Table 12: Summary of the Minor Therapeutic Classes in CD, 201344

Table 13: Biosimilars Pipeline, 201347

Table 14: Overall Unmet Needs in CD – Current Level of Attainment51

Table 15: Clinical Unmet Needs in CD – Gap Analysis, 201354

Table 16: Promising Drugs in Clinical Development for CD – Pipeline Phase, 201357

Table 17: Comparison of Therapeutic Classes in Development for CD, 201358

Table 18: Product Profile – Entyvio60

Table 19: Efficacy of Entyvio in GEMINI II Studies of CD61

Table 20: Entyvio SWOT Analysis, 201369

Table 21: Product Profile – Stelara71

Table 22: Comparison of Stelara’s Phase IIb CERTIFI trial Efficacy Data Versus Tysabri’s Phase III Efficacy Data in Anti-TNF Refractory CD Patients72

Table 23: Stelara SWOT Analysis, 201376

Table 24: Product Profile – Vercirnon78

Table 25: Vercirnon SWOT Analysis, 201382

Table 26: Product Profile – Prochymal84

Table 27: Prochymal SWOT Analysis, 201387

Table 28: Product Profile – Cx60189

Table 29: Cx601 SWOT Analysis, 201390

Table 30: Product Profile – RHB-10492

Table 31: RHB-104 SWOT Analysis, 201394

Table 32: Global CD Market – Drivers and Barriers, 2012–202295

Table 33: Sales Forecasts ($) for CD in Canada, 2012–2022102

Table 34: Key Events Impacting Sales for CD in Canada, 2012–2022104

Table 35: CD Market in Canada – Drivers and Barriers, 2012–2022104

Table 36: Key Launch Dates116

Table 37: Key Patent Expiries116

Table 38: Physicians Surveyed, By Country122

List of figures

Figure 1: CD: Canada Sales by Therapeutic Class, 2012–20229

Figure 2: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With ...

Figure 1: CD: Canada Sales by Therapeutic Class, 2012–20229

Figure 2: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right)15

Figure 3: Potential Biologic Drug Targets for CD17

Figure 4: Patient Care Path for CD23

Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012–202257

Figure 6: Sales for CD in Canada by Drug Class, 2012–2022103


Discounts available for multiple report purchases.
+44 (0) 161 359 5813

Saved reports